Table 1.

Clinicopathologic factors for patients undergoing breast conserving therapy

Factor	Surgery First (n=2331)	Neoadjuvant Chemotherapy (n=652)	P value
Age
Median	55	50	< 0.001
Range	22 – 89	25 - 84
Histology
IDC	2033 (87%)	617 (95%)	<0.001
ILC	169 (7%)	19 (3%)
Mixed	129 (6%)	16 (2%)
Clinical Stage
0	31* (1%)	0 (0%)	<0.001
I	1823 (78%)	45 (7%)
II	459 (20%)	451 (69%)
III	18 (1%)	156 (24%)
Nuclear grade
1	266 (11%)	16 (2%)	<0.001
2	1244 (53%)	196 (30%)
3	785 (34%)	431 (66%)
Not reported	36 (2%)	9 (1%)
ER
Positive	1665 (71%)	331 (51%)	<0.001
Negative	552 (24%)	311 (48%)
Unknown	114 (5%)	10 (1%)
PR
Positive	1364 (59%)	292 (45%)	<0.001
Negative	802 (34%)	347 (53%)
Unknown	165 (7%)	13 (2%)
HER2
Positive	122 (5%)	114 (17%)	<0.001
Negative	1216 (52%)	402 (62%)
Unknown	993 (43%)	136 (21%)
LVI
Present	348 (15%)	103 (16%)	0.584
Absent/Unknown	1983 (85%)	549 (84%)
Multifocal disease
Yes	155 (7%)	64 (10%)	0.006
No	2176 (93%)	588 (90%)
Margin Status
Negative	2239 (96%)	621 (95%)	0.144
Close (<2mm)	63 (3%)	26 (4%)
Positive	29 (1%)	5 (1%)
Pathologic Stage
0	0 (0%)	131 (20%)	<0.001
I	1540 (66%)	217 (33%)
II	702 (30%)	251 (38%)
III	89 (4%)	53 (9%)
Adjuvant
Chemotherapy
Yes	980 (42%)	NA	NA
No	1348 (58%)
Unknown	4 (<1%)
Endocrine Therapy§
Yes	1293 (78%)	294 (89%)	<0.001
No	372 (22%)	37 (11%)

Abbreviations: IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; Mixed, invasive ductal and lobular carcinoma; ER, estrogen receptor; PR, progesterone receptor; HER2, HER2/neu; LVI, lymphovascular invasion

^*31 patients who underwent surgery first had a biopsy diagnosis of ductal carcinoma in situ but were found to have invasive disease on final pathologic evaluation.

^§Administration of endocrine therapy was determined only for patients with ER-positive disease